Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Cited by (1,001)

Items 401–500 of 1,001

1. The promises and challenges of using gene mutations for patient stratification in follicular lymphoma
   Oliver Weigert, David M. Weinstock · 2017 · Blood
2. Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib
   Jari M. Tuomi, Anargyros Xenocostas, Douglas L. Jones · 2017 · Canadian Journal of Cardiology
3. Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
   Nathan Denlinger, Narendranath Epperla, Basem Magdy William · 2018 · Cancer Management and Research
4. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors
   Zhen Zhang, Daoguang Zhang, Yang Liu, Dezhi Yang, Fansheng Ran, Michael L. Wang, Guisen Zhao · 2018 · Archiv der Pharmazie
5. Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
   Xia Yin Yao, Xiuyun Sun, Shuyu Jin, Ling Lin Yang, Hongjiang Xu, Yu Rao · 2019 · Journal of Medicinal Chemistry
6. Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma
   Cho-Hao Lin, Khadija H. Elkholy, Nissar Ahmad Wani, Li Ding, Peng Hu, Juan Martin Barajas, Lianbo Yu, Xiaoli Zhang, Samson T. Jacob, Wasif Noor Khan et al. · 2019 · Molecular Cancer Therapeutics
7. Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma
   Fansheng Ran, Yang Liu, Shengping Yu, Kaiwen Guo, Wendi Tang, Xin Chen, Guisen Zhao · 2019 · Bioorganic Chemistry
8. Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants
   Ian M. Catlett, Miroslawa Nowak, Sudeep Kundu, Naiyu Zheng, Ang Liu, Bing He, Ihab G. Girgis, Dennis M. Grasela · 2020 · British Journal of Clinical Pharmacology
9. BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma
   Mehreen Ishfaq, Timothy V. Pham, Cooper Beaman, Pablo Tamayo, Alice Lin-Tsing Yu, Shweta Joshi · 2021 · Cancers
10. The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders
    Melanie C. Dispenza · 2021 · Current Treatment Options in Allergy
11. Novel Bruton's tyrosine kinase inhibitors currently in development
    Fatih Mehmet Uckun, D'Cruz · 2013 · OncoTargets and Therapy
12. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
    Deborah Marie Stephens, Stephen E. F. Spurgeon · 2015 · Therapeutic Advances in Hematology
13. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma
    Shelby L. Sloan, Fiona Brown-Burke, Mackenzie Long, Christoph Weigel, Shirsha Koirala, Ji-Hyun Chung, Betsy A. Pray, Lynda Villagomez, Claire Hinterschied, Anuvrat Sircar et al. · 2023 · Blood
14. The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies
    Kenneth H. Shain, Jianguo Tao · 2013 · Oncogene
15. 4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies
    Raimon Puig de la Bellacasa, Gaël Roué, Patricia Balsas, Patricia Pérez‐Galán, Jordi Teixidó, Dolors Colomer, José Ignacio Borrell · 2014 · European Journal of Medicinal Chemistry
16. Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
    Xiaohui Zheng, Ning Ding, Yuqin Song, Lixia Feng, Jun Zhu · 2014 · Cancer Cell International
17. Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders
    Jorge Julio Castillo, Steven Peter Treon, Matthew Steven Davids · 2016 · The Cancer Journal
18. Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on
    Stefano Molica, Estella Matutes, Constantine Si Lun Tam, Aaron Polliack · 2019 · Hematological Oncology
19. Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro
    Meijing Liu, Xuelin Wang, Zheng Li, Rui Zhang, Juan Mu, Yanyu Jiang, Qi Deng, Lei Sun · 2020 · Cancer Science
20. Richter Syndrome
    Davide Rossi, Gianluca Gaïdano · 2013 · Advances in experimental medicine and biology
21. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eμ-TCL1 mouse model
    Antonella Bresin, Elisa Callegari, Lucilla D’Abundo, Caterina Cattani, Cristian Bassi, Barbara Zagatti, Maria Grazia Narducci, Elisabetta Caprini, Yuri Pekarsky, Carlo Maria Croce et al. · 2015 · Oncotarget
22. The role of B cell antigen receptors in mantle cell lymphoma
    Michael W. Fichtner, Martin H. Dreyling, Mascha Binder, Martin Trepel · 2017 · Journal of Hematology & Oncology
23. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib
    Jacqueline C. Barrientos, Jan A. Burger, John C. Byrd, Peter Hillmen, Cathy Zhou, Joi Suzuki Ninomoto, Danelle Frances James, Thomas J. Kipps · 2018 · Leukemia & lymphoma/Leukemia and lymphoma
24. Bruton's tyrosine kinase inhibitors in B‐cell non‐Hodgkin's lymphomas
    Lapo Alinari, Carl D. Quinion, KA Blum · 2015 · Clinical Pharmacology & Therapeutics
25. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
    Jingjing Wu, Mingzhi Zhang, Delong Liu · 2016 · Oncotarget
26. Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen
    Michael Schäffer, Shalini Chaturvedi, Cuc Davis, Regina Aquino, Emily Stepanchick, Matthias Versele, Yang Liu, Jennifer Yang, Rongzhen Lu, Sriram Balasubramanian · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
27. The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
    Nathan Hale Fowler, Loretta J. Nastoupil, Sven de Vos, Mark H. Knapp, Ian W. Flinn, Robert Chen, Ranjana H. Advani, Sumeet Bhatia, Peter Martin, Raul R. Mena et al. · 2020 · British Journal of Haematology
28. Targeting the FcεRI Pathway as a Potential Strategy to Prevent Food-Induced Anaphylaxis
    Melanie C. Dispenza, Bruce Scott Bochner, Donald W. MacGlashan · 2020 · Frontiers in Immunology
29. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
    Deborah Marie Stephens, Ying Huang, Amy S. Ruppert, Janek S. Walker, Daniel Canfield, Casey B. Cempre, Qiang Fu, Sharyn D. Baker, Boyu Hu, Harsh Shah et al. · 2022 · Clinical Cancer Research
30. Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing
    Jason R. Burchett, Jordan M. Dailey, Sydney Ann Kee, Destiny T. Pryor, Aditya Kotha, Roma A. Kankaria, David B. Straus, John Jake Ryan · 2022 · Cells
31. Mini-Review: Bmx Kinase Inhibitors for Cancer Therapy
    John S. Jarboe, Shilpa Dutta, Sadanandan E. Velu, Christopher Douglas Willey · 2013 · Recent Patents on Anti-Cancer Drug Discovery
32. Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study
    Jan de Jong, Peter Hellemans, James Juhui Jiao, Yuhan Huang, Sofie Mesens, Juthamas Sukbuntherng, Danièle Ouellet · 2017 · Cancer Chemotherapy and Pharmacology
33. Novel Targeted Therapies in Diffuse Large B-Cell Lymphoma
    Neha Mehta–Shah, Anas Younes · 2015 · Seminars in Hematology
34. Current understanding of tyrosine kinase BMX in inflammation and its inhibitors
    Xu‐Lin Chen, Le Qiu, Fei Wang, Sheng Liu · 2014 · Burns & Trauma
35. Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade
    Sarah E. M. Herman, Adrian U. Wiestner · 2016 · Seminars in Oncology
36. An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL
    Sigrid Strand Skånland, Andrea Cremaschi, Henrik Bendiksen, Johanne Uthus Hermansen, Deepak B. Thimiri Govinda Raj, Ludvig A. Munthe, Geir Erland Tjønnfjord, Kjetil Taskén · 2019 · Leukemia
37. Extrahepatic metabolism of ibrutinib
    Johannes J.M. Rood, Amer Jamalpoor, Stéphanie van Hoppe, Matthijs J. van Haren, Roeland E. Wasmann, Manoe Jacoba Janssen, Alfred H. Schinkel, Rosalinde Masereeuw, Jos H. Beijnen, Rolf W. Sparidans · 2020 · Investigational New Drugs
38. Epstein–Barr virus LMP1 protein promotes proliferation and inhibits differentiation of epithelial cells via activation of YAP and TAZ
    Deo R. Singh, Scott E. Nelson, Abigail S. Pawelski, Alisha S. Kansra, Stuart A. Fogarty, Jillian A. Bristol, Makoto Ohashi, Eric Johannsen, Shannon C. Kenney · 2023 · Proceedings of the National Academy of Sciences
39. Ibrutinib-A double-edge sword in cancer and autoimmune disorders
    Parviz Kokhaei, Farhad Jadidi‐Niaragh, Abdolreza Sotoodeh Jahromi, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat‐Farsangi · 2015 · Journal of drug targeting
40. Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma
    Apurvasena Parikh, Sathej Gopalakrishnan, Kevin Jay Freise, Maria E. Verdugo, Rajeev M Menon, Sven Mensing, Ahmed Hamed Salem · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
41. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target
    Fortunato Morabito, Massimo Gentile, John Francis Seymour, Aaron Polliack · 2015 · Leukemia & lymphoma/Leukemia and lymphoma
42. Ibrutinib in Chronic Lymphocytic Leukemia
    Nishitha M Reddy, Tarsheen Kaur Sethi · 2015 · International Journal of Hematologic Oncology
43. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
    Chaim Shustik, Isabelle Bence‐Bruckler, Robert Delage, Carolyn Owen, Cynthia L. Toze, Steven E. Coutre · 2017 · Annals of Hematology
44. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia
    Uri Rozovski, David Harris, Ping Li, Zhiming Liu, Preetesh Jain, Alessandra Ferrajoli, Jan A. Burger, Philip A. Thompson, Nitin Jain, William G. Wierda et al. · 2018 · Leukemia & lymphoma/Leukemia and lymphoma
45. Fatty acid beta oxidation enzyme HADHA is a novel potential therapeutic target in malignant lymphoma
    Kouhei Yamamoto, Shinya Abe, Ayaka Honda, Jun Hashi­moto, Yuuki Aizawa, Sachiko Ishibashi, Taro Takemura, Nobutaka Hanagata, Masahide Yamamoto, Osamu Miura et al. · 2019 · Laboratory Investigation
46. Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies
    Alexey Valeryevich Danilov, Daniel Oscar Persky · 2020 · British Journal of Haematology
47. Ibrutinib’s Cardiotoxicity—An Opportunity for Postmarketing Regulation
    Mark J. Ratain, Javid J. Moslehi, Allen S. Lichter · 2020 · JAMA Oncology
48. Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target
    Carlos Cuesta‐Mateos, Jennifer R. Brown, Fernando Terrón, Cecilia Muñoz‐Calleja · 2021 · Frontiers in Immunology
49. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B‐cell receptor structure, function, and patients' prognosis
    Ilaria Del Giudice, Sabina Chiaretti, Simona Santangelo, Simona Tavolaro, Nadia Peragine, Marilisa Marinelli, Caterina Ilari, Sara Raponi, Monica Messina, Mauro Nanni et al. · 2013 · American Journal of Hematology
50. Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies
    Minh Ngoc Duong, Eva‐Laure Matera, Doriane Mathé, Anne Evesque, Sandrine Valsesia‐Wittmann, Béatrice Clemenceau, Charles Dumontet · 2014 · mAbs
51. Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells
    Stuart A. Rushworth, Genevra Pillinger, Amina M Abdul-Aziz, Rachel E. Piddock, Manar S. Shafat, Megan Y. Murray, Lyubov Zaitseva, Matthew J. Lawes, David J. MacEwan, Kristian M. Bowles · 2015 · The Lancet Haematology
52. CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma
    Hilka Rauert‐Wunderlich, Martina Rudelius, Ingolf Berberich, Andreas Rosenwald · 2018 · Cell Death and Disease
53. Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience
    AnnaLynn M. Williams, Andrea M Baran, Carla Casulo, Patrick Michael Reagan, Jonathan W. Friedberg, Margaret Helber, Jeremiah E. Moore, Elizabeth Baloga, Clive S. Zent, Paul M. Barr · 2018 · Clinical Lymphoma Myeloma & Leukemia
54. The CLL Cell Microenvironment
    Jan A. Burger · 2013 · Advances in experimental medicine and biology
55. Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia
    Varinder Kaur, Paulette Mehta, Joyce Johnsurd, Rangaswamy Govindarajan · 2014 · Blood
56. A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia
    Leslie Ann Andritsos, John C. Byrd, Peter Cheverton, Jingyang Wu, Mariela Sivina, Thomas J. Kipps, Jan A. Burger · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
57. Dose Finding Study of Ibrutinib and Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma
    Craig Anthony Portell, Nolan A. Wages, Brad S. Kahl, Lihua Elizabeth Budde, Robert W. Chen, Jonathon Brett Cohen, Nikole Varhegyi, Gina R. Petroni, Michael E. Williams · 2021 · Blood Advances
58. The Importance of Tracking “Missing” Metabolites: How and Why?
    Shuai Wang, T. Eric Ballard, Lisa J. Christopher, R. Foti, Chungang Gu, Siamak Cyrus Khojasteh, Joyce Liu, Shuguang Ma, Bin Ma, Ronald Scott Obach et al. · 2023 · Journal of Medicinal Chemistry
59. Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma.
    Nader Kim El‐Mallawany, Mitchell Stuart Cairo · 2015 · PubMed
60. Therapeutic benefits targeting B-cells in chronic graft-versus-host disease
    Hideki Nakasone, Bita Sahaf, David Bernard Miklos · 2015 · International Journal of Hematology
61. Non-Hodgkin Lymphoma Metabolism
    Brian James Kirsch, Shu‐Jyuan Chang, Anne Le · 2018 · Advances in experimental medicine and biology
62. Design and synthesis of novel pyrazolo[4,3- d ]pyrimidines as potential therapeutic agents for acute lung injury
    Bao Shi Wang, Xin Huang, Liu Zeng Chen, Ming Ming Liu, Jing Bo Shi · 2019 · Journal of Enzyme Inhibition and Medicinal Chemistry
63. The HDAC6‐selective inhibitor is effective against non‐Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma
    Dong Hoon Lee, Go Woon Kim, So Hee Kwon · 2019 · Molecular Carcinogenesis
64. A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
    Simon A. Rule, David L. Tucker · 2015 · Therapeutics and Clinical Risk Management
65. The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia
    Julia Christine Gutjahr, Richard Greil, Tanja Nicole Hartmann · 2015 · Frontiers in Immunology
66. Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors
    Jing Ren, Wei Shi, Damin Zhao, Qinglin Wang, Xiayun Chang, Xiangyi He, Xiaojin Wang, Yong Gao, Peng Lü, Xiquan Zhang et al. · 2019 · Bioorganic & Medicinal Chemistry
67. The effect of ibrutinib on neutrophil and γδ T cell functions
    Denise Risnik, Esteban E. Elías, Irene Angélica Keitelman, Ana Colado, Enrique Podaza, Gregorio Cordini, Maricef Vergara Rubio, Horacio Fernández Grecco, Raimundo Fernando Bezares, Mercedes Borge et al. · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
68. Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Rachael Arthur, Beatriz Valle‐Argos, Andrew J. Steele, Graham Packham · 2020 · Exploration of Targeted Anti-tumor Therapy
69. Achieving Incompatible Transplantation through Desensitization: Current Perspectives and Future Directions
    Stanley C. Jordan, Jua Choi, Ashley A. Vo · 2015 · Immunotherapy
70. Novel agents for relapsed and refractory follicular lymphoma
    Chan Yoon Cheah, Nathan Hale Fowler · 2017 · Best Practice & Research Clinical Haematology
71. Management of Drug Resistance in Mantle Cell Lymphoma
    Gaël Roué, Brigitte Sola · 2020 · Cancers
72. B cell signalling pathways—New targets for precision medicine in chronic lymphocytic leukaemia
    Sigrid Strand Skånland, Linda Karlsen, Kjetil Taskén · 2020 · Scandinavian Journal of Immunology
73. Ibrutinib in B-cell lymphoma: single fighter might be enough?
    Chao Xue, Xin Wang, Lingyan Zhang, Qingyuan Qu, Qian Zhang, Yujie Jiang · 2020 · Cancer Cell International
74. Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy
    Salvatrice Mancuso, Marta Mattana, Melania Carlisi, Marco Santoro, Sergio Mario Siragusa · 2022 · International Journal of Molecular Sciences
75. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment
    Ailin Guo, Ping Lü, Justine C. Lee, Chenxiang Zhen, Gabriela Chiosis, Y. Lynn Wang · 2017 · Oncogene
76. Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy
    Reem Karmali, Leo I. Gordon · 2017 · Current Treatment Options in Oncology
77. Improving physicochemical properties of Ibrutinib with cocrystal strategy based on structures and natures of the carboxylic acid co-formers
    Xiangjun Shi, Chao Wang, Qifeng Chen, Shuimei Shen, Shengjie Song, Xiyue Zhou · 2021 · Journal of Drug Delivery Science and Technology
78. From development to clinical success: the journey of established and next-generation BTK inhibitors
    Shivani Gupta, Arpit Sharma, Alok Kumar Shukla, Abha Mishra, Amit Kumar Singh · 2025 · Investigational New Drugs
79. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
    Emili Montserrat, Peter Dreger · 2016 · Clinical Lymphoma Myeloma & Leukemia
80. Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model
    Yaya Chu, Sanghoon Lee, Tishi Shah, Changhong Yin, Matthew John Barth, Rodney R. Miles, Janet S Ayello, Erin Morris, Lauren Harrison, Carmella van de Ven et al. · 2018 · OncoImmunology
81. Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
    Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Despina Fotiou, Meletios Athanasios Dimopoulos · 2021 · Therapeutic Advances in Hematology
82. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
    Jorge Julio Castillo, Christian Buske, Judith Trotman, Shayna Sarosiek, Steven Peter Treon · 2022 · American Journal of Hematology
83. Murine Genetically Engineered and Human Xenograft Models of Chronic Lymphocytic Leukemia
    Shih‐Shih Chen, Nicholas Chiorazzi · 2014 · Seminars in Hematology
84. The Expression of Sphingosine-1 Phosphate Receptor-1 in Chronic Lymphocytic Leukemia Cells Is Impaired by Tumor Microenvironmental Signals and Enhanced by Piceatannol and R406
    Mercedes Borge, Federico Remes Lenicov, Paula Romina Nannini, María Mercedes De Los Ríos Alicandú, Enrique Podaza, Ana Ceballos, Horacio Fernández Grecco, María Cabrejo, Raimundo Fernando Bezares, Pablo Elías Morande et al. · 2014 · The Journal of Immunology
85. Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment*
    Jan de Jong, Donna M. Skee, Peter Hellemans, James Juhui Jiao, Ronald de Vries, Dominique Swerts, Eric Lawitz, Thomas C Marbury, William Smith, Juthamas Sukbuntherng et al. · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
86. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014
    Frederick R. Appelbaum, Claudio Anasetti, Joseph H. Antin, Harold L. Atkins, Stella M. Davies, Steven Michael Devine, Sergio Giralt, Helen Elisabeth Heslop, Ginna G. Laport, Stephanie Joi Lee et al. · 2014 · Transplantation and Cellular Therapy
87. A non‐covalent inhibitor XMU‐MP‐3 overrides ibrutinib‐resistant BtkC481S mutation in B‐cell malignancies
    Fu Gui, Jie Jiang, Zhixiang He, Li Li, Yunzhan Li, Zhou Deng, Yue Lu, Xinrui Wu, Guyue Chen, Jingyi Su et al. · 2019 · British Journal of Pharmacology
88. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP
    Ying C. Ou, Zhiyu Tang, William F. Novotny, Manal Tawashi, Ta-Kai Li, H. Coleman, Srikumar Sahasranaman · 2020 · British Journal of Clinical Pharmacology
89. Potential applications of Bruton’s tyrosine kinase inhibitors for the prevention of allergic reactions
    Melanie C. Dispenza, Jennifer A. Regan, Bruce Scott Bochner · 2017 · Expert Review of Clinical Immunology
90. Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways
    Julie Langlois, Simona Lange, Martin Ebeling, Will Macnair, Roland Schmucki, Cenxiao Li, Jonathan DeGeer, Tania J. J. Sudharshan, Voon Wee Yong, Yun‐An A. Shen et al. · 2024 · Journal of Neuroinflammation
91. Novel Treatments for Chronic Lymphocytic Leukemia and Moving Forward
    Jennifer R. Brown, David L. Porter, Susan Mary O'Brien · 2014 · American Society of Clinical Oncology Educational Book
92. The current status and future impact of targeted therapies in non-Hodgkin lymphoma
    Chaitra Shankar Ujjani, Bruce D. Cheson · 2013 · Expert Review of Hematology
93. The HELIOS Trial Protocol: A Phase III Study of Ibrutinib in Combination with Bendamustine and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Michael J. Hallek, Neil E. Kay, Anders Österborg, Asher Alban Chanan-Khan, Michelle Mahler, Mariya Salman, Ying Wan, Steven H. Sun, Sen Hong Zhuang, Angela J. Howes · 2014 · Future Oncology
94. Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
    Max Von Suskil, Kazi Nasrin Sultana, Weam Othman Elbezanti, Omar S. Al‐Odat, Robert J. Chitren, Amit Kumar Tiwari, Kishore B. Challagundla, Sandeep Kumar Srivastava, Subash C. Jonnalagadda, Tülin Budak-Alpdoǧan et al. · 2021 · International Journal of Molecular Sciences
95. Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib
    Shayna Sarosiek, Joshua N. Gustine, Catherine A. Flynn, Carly R. Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven Peter Treon, Jorge Julio Castillo · 2023 · British Journal of Haematology
96. The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies
    Valkal Bhatt, Linh Alejandro, Angela Michael, Alex Ganetsky · 2013 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
97. Potential of protein kinase inhibitors for treating herpesvirus-associated disease
    Renfeng Li, S. Diane Hayward · 2013 · Trends in Microbiology
98. Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia
    Viralkumar M. Patel, Michael J. Keating, William G. Wierda, Varsha V. Gandhi · 2015 · Leukemia & lymphoma/Leukemia and lymphoma
99. Ibrutinib in CLL/SLL: From bench to bedside (Review)
    Fuming Zi, Yu Li, Qingzhi Shi, Aiping Tang, Jing Cheng · 2019 · Oncology Reports
100. Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
     Lauren E. Kueffer, Raji E. Joseph, Amy Hamilton Andreotti · 2021 · Frontiers in Cell and Developmental Biology